British American Tobacco is providing a £100 million financing commitment to facilitate the merger of Organigram and Aurora Cannabis. This strategic investment aims to create a combined entity with expanded operations in recreational and medical cannabis across key international markets.
British American Tobacco (BTI) is acting as a strategic investor, providing a £100 million financing commitment to support the merger of Organigram (OGI) and Aurora Cannabis (ACB). This deal is significant as it combines Organigram's recreational cannabis operations with Aurora's international medical cannabis business, aiming to expand their presence across Canada, Europe, and Australia. For traders, this represents a potential long-term growth opportunity for OGI and ACB as they consolidate and expand their market reach, backed by a major investor. The short-term impact could see increased investor interest in both cannabis companies, while BTI's involvement signals a continued strategic pivot into the cannabis sector, potentially diversifying its revenue streams.